{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Autoinflammatory syndrome",
      "Inflammasome",
      "Interleukin1",
      "Interleukine 1",
      "Syndrome auto-inflammatoire",
      "TNFRFS1A",
      "TNFRSF1A",
      "TRAPS",
      "TRAPS syndrome"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29525418",
  "DateCompleted": {
    "Year": "2018",
    "Month": "10",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "10",
    "Day": "24"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "03",
        "Day": "07"
      }
    ],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "10.1016/j.revmed.2018.02.002",
      "S0248-8663(18)30038-9"
    ],
    "Journal": {
      "ISSN": "1768-3122",
      "JournalIssue": {
        "Volume": "39",
        "Issue": "4",
        "PubDate": {
          "Year": "2018",
          "Month": "Apr"
        }
      },
      "Title": "La Revue de medecine interne",
      "ISOAbbreviation": "Rev Med Interne"
    },
    "ArticleTitle": "[Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].",
    "Pagination": {
      "StartPage": "256",
      "EndPage": "264",
      "MedlinePgn": "256-264"
    },
    "Abstract": {
      "AbstractText": [
        "Tumour necrosis receptor associated periodic syndrome (TRAPS) is a rare cosmopolitan dominant autosomal disease that belongs to the group of recurrent autoinflammatory syndromes. TRAPS is characterized by recurrent bouts of fever lasting more than 7 days, with arthralgia, myalgia, abdominal pain, erythematous rash and sometimes ocular symptoms. During flares, raised inflammatory markers are constant. The age of onset may occur during childhood but also during adulthood. TRAPS is caused by mutations in the TNF receptor 1 (TNFRSF1A) gene that may occur in most of the populations over the world. In the majority of patients, history shows affected relatives, even if sporadic cases do exist. Management of TRAPS usually involves corticosteroid therapy during inflammatory flares. The most severe cases require a treatment with biological agents (mainly interleukin 1 inhibitors). The prognosis of TRAPS is overall good; the main risk is represented by the development of secondary inflammatory amyloidosis. This risk is greatest in patients with structural mutations leading to conformation abnormalities of the TNFRSF1A receptor. Regular clinical and biological monitoring is essential in the follow-up of TRAPS patients."
      ],
      "CopyrightInformation": "Copyright \u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier SAS. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne, h\u00f4pital Tenon, 4, rue de la Chine, Assistance publique-H\u00f4pitaux de Paris (AP-HP), universit\u00e9 Paris 6, Pierre-et-Marie-Curie (UPMC), 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; INSERM UMRS_933, h\u00f4pital Trousseau, universit\u00e9 Pierre-et-Marie-Curie (UPMC)-Paris 6, Assistance publique-H\u00f4pitaux de Paris, 75012 Paris, France."
          }
        ],
        "LastName": "Georgin-Lavialle",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; Service de rhumatologie p\u00e9diatrique, universit\u00e9 de Paris Sud, CHU de Bic\u00eatre, Assistance publique-H\u00f4pitaux de Paris, 94270 le Kremlin-Bic\u00eatre, France."
          }
        ],
        "LastName": "Kone-Paut",
        "ForeName": "I",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne, h\u00f4pital Tenon, 4, rue de la Chine, Assistance publique-H\u00f4pitaux de Paris (AP-HP), universit\u00e9 Paris 6, Pierre-et-Marie-Curie (UPMC), 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France."
          }
        ],
        "LastName": "Delaleu",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; Laboratoire de g\u00e9n\u00e9tique, CHU de Montpellier, 191, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France."
          }
        ],
        "LastName": "Sarrabay",
        "ForeName": "G",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne, h\u00f4pital Tenon, 4, rue de la Chine, Assistance publique-H\u00f4pitaux de Paris (AP-HP), universit\u00e9 Paris 6, Pierre-et-Marie-Curie (UPMC), 75020 Paris, France; Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; INSERM UMRS_933, h\u00f4pital Trousseau, universit\u00e9 Pierre-et-Marie-Curie (UPMC)-Paris 6, Assistance publique-H\u00f4pitaux de Paris, 75012 Paris, France."
          }
        ],
        "LastName": "Grateau",
        "ForeName": "G",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; Laboratoire de g\u00e9n\u00e9tique, CHU de Montpellier, 191, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France."
          }
        ],
        "LastName": "Touitou",
        "ForeName": "I",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre de r\u00e9f\u00e9rence des maladies auto-inflammatoires et de l'amylose inflammatoire, (CEREMAIA), France; Service de p\u00e9diatrie g\u00e9n\u00e9rale, centre hospitalier de Versailles, 179, rue de Versailles, 78150 Le Chesnay, France. Electronic address: vhentgen@ch-versailles.fr."
          }
        ],
        "LastName": "Hentgen",
        "ForeName": "V",
        "Initials": "V"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "La fi\u00e8vre r\u00e9currente li\u00e9e au r\u00e9cepteur 1\u00a0du TNF (TNF receptor associated periodic syndrome \u2013\u00a0TRAPS)."
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Med Interne",
    "NlmUniqueID": "8101383",
    "ISSNLinking": "0248-8663"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biological Factors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Glucocorticoids"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Inflammasomes"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Tumor Necrosis Factor, Type I"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "TNFRSF1A protein, human"
    }
  ],
  "SupplMeshList": [
    "Periodic fever, familial, autosomal dominant"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Biological Factors"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Glucocorticoids"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Hereditary Autoinflammatory Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Inflammasomes"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Interleukin-1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Receptors, Tumor Necrosis Factor, Type I"
    }
  ]
}